|
|
Post by sellhighdrinklow on Dec 18, 2017 12:35:08 GMT -5
This is the next catalyst that will move MNKD significantly up, IMHO. Does anybody know somebody at University Colorado, Denver (my recollection of where the study is taking place) who can find this info out? Little birdies....Castagna himself.....MNKD, IR..... Study is supposed to conclude end of December, this year.
How about somebody with Twitter asking Castagna this question. TYIA
|
|
|
|
Post by madog365 on Dec 18, 2017 12:58:45 GMT -5
Most likely at ADA 2018
|
|
|
|
Post by xanet on Dec 18, 2017 14:12:40 GMT -5
Yes, I emailed a colleague. They plan to present at ADA.
|
|
|
|
Post by kite on Dec 18, 2017 14:24:34 GMT -5
When will this conference take place? |
|
|
|
Post by babaoriley on Dec 18, 2017 14:27:09 GMT -5
Right around the corner in June, I believe.
|
|
|
|
Post by InvesterSam on Dec 18, 2017 14:41:29 GMT -5
|
|
|
|
Post by sellhighdrinklow on Dec 18, 2017 15:54:39 GMT -5
Yes, I emailed a colleague. They plan to present at ADA. Thank you, xanet. May I ask what business your colleague is in and connection(s) confirming this? |
|
|
|
Post by xanet on Dec 18, 2017 16:38:31 GMT -5
Yes, I emailed a colleague. They plan to present at ADA. Thank you, xanet. May I ask what business your colleague is in and connection(s) confirming this? He's a faculty member who works with the Barbara Davis Center for Diabetes. That's about as specific as I am comfortable being on a public forum. |
|
|
|
Post by cjm18 on Dec 18, 2017 16:46:56 GMT -5
June? So this is not a near term catalyst. Was it going to be a catalyst at all? I.e. help insurance coverage or convince doctors to prescribe?
|
|
|
|
Post by majorwood on Dec 18, 2017 16:51:30 GMT -5
My son is currently a student there. Maybe I'll get him to sniff around a little bit.
|
|
|
|
Post by xanet on Dec 18, 2017 20:11:11 GMT -5
June? So this is not a near term catalyst. Was it going to be a catalyst at all? I.e. help insurance coverage or convince doctors to prescribe? ADA is almost best case scenario. The standard approach in academia is to present at a conference, and follow-up with publication in a journal. The only other logical choice is to first publish in a journal, and that would delay it by several months. It would be extremely unusual to just announce the findings publicly outside of a conference or journal. That would generally mean the data was not sufficiently robust for publication. |
|
|
|
Post by mnholdem on Dec 18, 2017 21:11:55 GMT -5
The 2017 ADA stipulated that for presentations at their conferences, results may not be previously disseminated in any public forum. There was a great deal of grumbling about that throughout the industry as several major diabetes blogs took up the discussion. In spite of the public dissent, it's unlikely that the ADA has amended its quite restrictive rules for the 2018 ADA Scientific Sessions.
Publication in a journal may occur shortly/immediately after the ADA but probably not before.
|
|
|
|
Post by xanet on Dec 18, 2017 22:16:27 GMT -5
The 2017 ADA stipulated that for presentations at their conferences, results may not be previously disseminated in any public forum. There was a great deal of grumbling about that throughout the industry as several major diabetes blogs took up the discussion. In spite of the public dissent, it's unlikely that the ADA has amended its quite restrictive rules for the 2018 ADA Scientific Sessions. Publication in a journal may occur shortly/immediately after the ADA but probably not before. Good luck getting a paper through peer review that fast. The process takes awhile. |
|
|
|
Post by mnkdfann on Dec 18, 2017 22:25:35 GMT -5
The 2017 ADA stipulated that for presentations at their conferences, results may not be previously disseminated in any public forum. There was a great deal of grumbling about that throughout the industry as several major diabetes blogs took up the discussion. In spite of the public dissent, it's unlikely that the ADA has amended its quite restrictive rules for the 2018 ADA Scientific Sessions. Publication in a journal may occur shortly/immediately after the ADA but probably not before. Good luck getting a paper through peer review that fast. The process takes awhile. Here is the embargo policy for the 2017 ADA. professional.diabetes.org/content-page/embargo-policyHere it is for the 2018 ADA. professional.diabetes.org/content-page/embargo-policy-0Generally papers may not be PUBLISHED in advance of presentation, but they may be SUBMITTED for publication in advance of the ADA. So a paper presented at the ADA may well appear in print in a refereed journal very soon after. It is just a matter of planning / careful timing. It's not THAT tricky. (I speak from experience.) "If the accepted abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date that abides by the Association’s embargo policy. If publication occurs online or in print before the specific embargo date and time set by the Association, the abstract must be withdrawn." |
|
|
|
Post by pantaloons on Dec 18, 2017 22:53:52 GMT -5
In general, how would the results of a single clinical study affect insurance coverage and physician adoption of a drug? From what I understand, the STAT study is much more well designed than the original clinical trial for FDA approval of Afrezza. Additionally, the results are expected to be quite conclusive and compelling. From my naive understanding, it should be enough for significant improvement insurance coverage and physician adoption. However, I wanted to inquire others' thoughts on the impact of the STAT study, compared to historical standards in this area.
|
|
